Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488)
I · Intervention 중재 / 시술
adjuvant pembrolizumab/placebo Q3W for 9 cycles
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Trial registration ClinicalTrials.gov, NCT03036488 https://www. [CLINICALTRIALS] gov/study/NCT03036488.
[PURPOSE] We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cance
- 표본수 (n) 784
APA
Kuemmel S, Fasching PA, et al. (2026). Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.. Annals of surgical oncology. https://doi.org/10.1245/s10434-026-19121-2
MLA
Kuemmel S, et al.. "Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.." Annals of surgical oncology, 2026.
PMID
41739398 ↗
Abstract 한글 요약
[PURPOSE] We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 study (NCT03036488).
[METHODS] Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin and cyclophosphamide for 4 cycles. After definitive surgery, participants received adjuvant pembrolizumab/placebo Q3W for 9 cycles. Surgery type and timing, nodal status postsurgery, and adverse events within 30 days following surgery were recorded.
[RESULTS] Among 1,174 randomized participants (pembrolizumab plus chemotherapy, n = 784; placebo plus chemotherapy, n = 390), similar proportions underwent breast-conserving surgery (45.2% vs. 45.6%) and mastectomy (44.0% vs. 42.6%). Median (10th‒90th percentile) time from end of on-study neoadjuvant treatment to surgery was 1.2 (0.9‒1.9) months in the pembrolizumab plus chemotherapy group and 1.2 (0.9‒1.7) months in the placebo plus chemotherapy group. Median (10th‒90th percentile) time from surgery to adjuvant pembrolizumab/placebo was 2.6 (1.0‒3.9) months in the pembrolizumab plus chemotherapy group and 2.7 (1.1‒4.0) months in the placebo plus chemotherapy group. The only AE occurring in ≥5% of participants between 0 and 30 days postsurgery was procedural pain (7.0% vs. 5.8%). The rate of pathological complete nodal response at surgery was 76.7% in the pembrolizumab plus chemotherapy group versus 69.9% in the placebo plus chemotherapy group.
[CONCLUSIONS] These findings show that adding neoadjuvant pembrolizumab to chemotherapy had no adverse impact on surgical outcomes (including type, timing, and safety). Trial registration ClinicalTrials.gov, NCT03036488 https://www.
[CLINICALTRIALS] gov/study/NCT03036488.
[METHODS] Participants with previously untreated, early-stage TNBC (AJCC stage T1c N1-2 or T2-4 N0-2) were randomized 2:1 to neoadjuvant pembrolizumab/placebo plus paclitaxel-carboplatin for 4 cycles, followed by pembrolizumab/placebo plus doxorubicin/epirubicin and cyclophosphamide for 4 cycles. After definitive surgery, participants received adjuvant pembrolizumab/placebo Q3W for 9 cycles. Surgery type and timing, nodal status postsurgery, and adverse events within 30 days following surgery were recorded.
[RESULTS] Among 1,174 randomized participants (pembrolizumab plus chemotherapy, n = 784; placebo plus chemotherapy, n = 390), similar proportions underwent breast-conserving surgery (45.2% vs. 45.6%) and mastectomy (44.0% vs. 42.6%). Median (10th‒90th percentile) time from end of on-study neoadjuvant treatment to surgery was 1.2 (0.9‒1.9) months in the pembrolizumab plus chemotherapy group and 1.2 (0.9‒1.7) months in the placebo plus chemotherapy group. Median (10th‒90th percentile) time from surgery to adjuvant pembrolizumab/placebo was 2.6 (1.0‒3.9) months in the pembrolizumab plus chemotherapy group and 2.7 (1.1‒4.0) months in the placebo plus chemotherapy group. The only AE occurring in ≥5% of participants between 0 and 30 days postsurgery was procedural pain (7.0% vs. 5.8%). The rate of pathological complete nodal response at surgery was 76.7% in the pembrolizumab plus chemotherapy group versus 69.9% in the placebo plus chemotherapy group.
[CONCLUSIONS] These findings show that adding neoadjuvant pembrolizumab to chemotherapy had no adverse impact on surgical outcomes (including type, timing, and safety). Trial registration ClinicalTrials.gov, NCT03036488 https://www.
[CLINICALTRIALS] gov/study/NCT03036488.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
- ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
- Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.
- Impact of Comorbidities on Clinical Outcomes and Quality of Life of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer Treated With Palbociclib in the POLARIS Study.
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.
- Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article.